Compass Therapeutics, Inc. (CMPX) Institutional Ownership

Ownership Summary

A total of 122 institutions have reported a stake in Compass Therapeutics, Inc. (NASDAQ:CMPX) as of September 2025, according to recent 13F filings with the SEC.

• The percentage of Compass Therapeutics owned by institutions changed from 80.1% in June 2025 to 110.0% in September 2025, marking a slight up trend.
• Quarterly data indicates a 36.87% shift in institutional share volume, and the annual owner count reflects an increase of 56.41%.
• During the quarter, 71 institutions bought more Compass Therapeutics shares, 34 sold shares, and 17 of the 122 total investors held their position steady.
• Collectively, institutional investors increased their stake in Compass Therapeutics to 152.05Mn shares as of September 2025, a change that is up by 40.96Mn shares quarter on quarter and up 60.05Mn shares year over year.
• TANG CAPITAL MANAGEMENT LLC's holding of 16.81Mn shares as of September 30, 2025 makes it the primary institutional investor in Compass Therapeutics, owning 12.16% of the stock.
• Among the most significant buyers of Compass Therapeutics during September 2025 were SUVRETTA CAPITAL MANAGEMENT, LLC (6.95Mn), BVF INC/IL (4.75Mn), Vivo Capital, LLC (3.50Mn), TANG CAPITAL MANAGEMENT LLC (3.32Mn), BALYASNY ASSET MANAGEMENT L.P. (2.80Mn).
• Leading sellers of Compass Therapeutics stock in September 2025 included Caption Management, LLC (2.06Mn), MPM BioImpact LLC (546.53K), Rock Springs Capital Management LP (488.25K), SG Americas Securities, LLC (223.37K), Blackstone Inc. (185.04K).
• The top 10 institutional holders of Compass Therapeutics for the quarter ending September 2025 included TANG CAPITAL MANAGEMENT LLC (16.81Mn), ORBIMED ADVISORS LLC (15.22Mn), SUVRETTA CAPITAL MANAGEMENT, LLC (14.10Mn), Blackstone Inc. (9.84Mn), Vivo Capital, LLC (9.55Mn), Enavate Sciences GP, LLC (7.79Mn), BlackRock, Inc. (7.37Mn), VANGUARD GROUP INC (7.06Mn), ADAGE CAPITAL PARTNERS GP, L.L.C. (5.19Mn), MPM BioImpact LLC (5.08Mn).